204770-67-2

Basic information

• Product Name: Phenol, 4-(5-aminopyrazinyl)-
• CAS NO: 204770-67-2
• Molecular Formula: C10H9N3O
• Molecular Weight: 187.201
• Mol File: 204770-67-2.mol

Chemical Properties

• CAS DataBase Reference: Phenol, 4-(5-aminopyrazinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-(5-aminopyrazinyl)-(204770-67-2)
• EPA Substance Registry System: Phenol, 4-(5-aminopyrazinyl)-(204770-67-2)

Safety Data

• Hazardous Substances Data: 204770-67-2(Hazardous Substances Data)

Upstream product

• 144465-03-2 N-[5-(4-Methoxy-phenyl)-pyrazin-2-yl]-acetamide 
• 59489-71-3 5-amino-2-bromopyrazine 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 5720-07-0 4-methoxyphenylboronic acid 
• 119738-50-0 2-amino-5-(4'-methoxyphenyl)-1,4-pyrazine 

Downstream Products

• 204770-68-3 4-[4-(5-Amino-pyrazin-2-yl)-phenoxy]-butyric acid ethyl ester 
• 1246302-64-6 2-phenyl-6-p-hydroxyphenylimidazo[1,2-a]pyrazin-3(7H)-imine hydrochloride 
• 204770-69-4 4-[4-(2-Methyl-3-oxo-3,7-dihydro-imidazo[1,2-a]pyrazin-6-yl)-phenoxy]-butyric acid 
• 212253-68-4 4-[4-(5-Acetylamino-pyrazin-2-yl)-phenoxy]-butyric acid 

Relevant articles and documents

In vitro and in vivo studies of 6,8-(diaryl)imidazo[1,2-a]pyrazin-3(7H)-ones as new antioxidants

A series of 5-aryl and 3,5-diaryl-2-amino-1,4-pyrazines and the derived imidazopyrazinones has been synthesized to study the chemical oxidative degradation of the bicyclic systems in vitro. Imidazopyrazinones mainly degraded following two independent pathways producing their precursors, namely aminopyrazines, and the corresponding amidopyrazines, respectively. Despite the fact that there is no influence of the substituent of the 3-aryl group on the ratio of the products aminopyrazine/amidopyrazine, diarylimidazopyrazinones and diarylaminopyrazines are good antioxidants in vivo. They protected against microvascular damages in ischemia/reperfusion with similar efficiencies.

Spiro compounds

Compounds of the general formula (I): wherein Ar1represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Novel spiro compounds

Compounds of the general formula (I): wherein Ar1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents nitrogen; Y represents an optionally substituted imino or oxygen atom, which exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.

Catechol derivatives of aminopyrazine and cell protection against uvb-induced mortality

A series of 5-aryl- and 3,5-bis-aryl-2-amino-1,4-pyrazine derivatives 4 and 6, and related imidazolopyrazinones 7, has been synthesized, the aryl groups of which are catechol and/or phenol substituents. These compounds, tested against human keratinocyte c

Synthesis and enhanced chemiluminescence of new cyclomaltooligosaccharide (cyclodextrin) -bound 6-phenylimidazo[1,2- a]pyrazin-3(7H)-one

In order to provide chemiluminescent substrates that have high light- emitting efficiency in aqueous solution, the structural design on 6- phenylimidazo[1,2-a]pyrazin-3(7H)-one compounds was studied in the covalent attachment of a light-producing chromophore to a cyclomaltooligosaccharide (cyclodextrin). The synthesis of cyclodextrin-bound 6-phenylimidazo[1,2- a]pyrazin-3(7H)-one compounds was achieved by the formation of an amido bond between a 6-phenylimidazo[l,2-a]pyrazin-3(7H)-one and a mono-6-amino-6- deoxycyclodextrin. The properties of oxygen-induced chemiluminescence of the synthesized cyclodextrin-bound light-emitting chromophores were investigated. The light-emitting efficiency in pH 8.3 phosphate buffer was remarkably dependent on the kind of bound cyclodextrin and the binding site between the chromophore and cyclodextrin. The light-emitting efficiency of a cyclodextrin-bound compound in which cyclomaltoheptaose (β-cyclodextrin) had been covalently attached to the 2-position of the imidazo[1,2-a]pyrazin- 3(7H)-one ring system showed an up to 11-fold enhancement over that of a non- cyclodextrin chromophore, whereas attachment to cyclomaltohexaose (α- cyclodextrin) resulted in no enhancement. Moreover, this study indicated that the strategy that involves covalently attaching a light-producing chromophore onto a cyclodextrin for the enhancement of chemiluminescence is more efficient than the use of an aqueous solution containing very large amounts of cyclodextrin.